A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)

#3245

Introduction: The NETTER-1 trial showed that patients with midgut neuroendocrine tumors (NETs) had longer progression-free survival (PFS) when treated with peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in combination with octreotide LAR vs octreotide LAR alone.

Aim(s): In this study, we present our experience with non-midgut NETs treated with PRRT.

Materials and methods: A total of 86 patients underwent PRRT from July 2018 to October 2020. 57/86 patients (29 women, 28 men; mean±SD: 61.3±10.6years-old) had progressive non-midgut, somatostatin receptor (SSR)-expressing tumors: 40/57 pancreatic, 4/57 foregut NETs, 7 NETs of unknown primary, 4 paragangliomas, and 2 pheochromocytomas. 68Ga-DOTATATE PET was obtained at baseline, after 2 cycles, and after 4 cycles. Follow-up imaging was performed every 3 months. Progression-free survival (PFS), interim overall survival (OS) and overall response rate (ORR) were calculated.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan H

Authors: Duan H, Ferri V, Fisher G, Shaheen S, Davidzon G,

Keywords: non-midgut NET, NET, PRRT, 177Lu-Dotatate,